About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

New Experimental Drug Shows Promising Result in Advanced Stage Cancer Treatment

by Madhumathi Palaniappan on December 1, 2016 at 2:43 PM
Font : A-A+

New Experimental Drug Shows Promising Result in Advanced Stage Cancer Treatment

New experimental drug called TAS-114 was found to increase the anti-cancer properties of chemotherapy drugs without increasing the side effects in cancer patients, finds a phase 1 clinical trial study presented at the 28th EORTC-NCI-AACR (1) Symposium on Molecular Targets and Cancer Therapeutics in Munich, Germany.

Dr Takekazu Aoyama, a surgeon and vice president of clinical development at Taiho Oncology Inc, Princeton, USA, described how TAS-114 in combination with another chemotherapy caused tumors to shrink in patients with advanced non-small cell lung cancer, pancreatic cancer, colorectal cancer and breast cancer. In addition, some patients whose cancer had failed to respond to other therapies were able to continue with the treatment and their disease remained stable without progressing for more than six months.

Advertisement


TAS-114 inhibits deoxyuridine triphosphatase (dUTPase) -- a 'gatekeeper' protein that acts on FdUTP, a metabolite of the anti-cancer drug 5-fluorouracil (5-FU), and restricts its incorporation into the DNA of cancer cells, thereby enabling the cells to continue living and proliferating. Research has already shown that tumors with high levels of dUTPase are resistant to 5-FU chemotherapy, and so successful inhibition of dUTPase may be an important step in enhancing the activity of 5-FU.

In the study presented today, researchers from Italy, Switzerland, France and Belgium, enrolled 92 patients into a phase I trial in which TAS-114 was given to patients together with a chemotherapy called S-1, which is a fixed-dose combination of tegafur, gimeracil and oteracil. Tegafur is the active anti-cancer agent, which, after administration, is converted by the body into the active form of 5-FU [2]; gimeracil inhibits the degradation of 5-FU, leading to higher 5-FU levels in the body for longer; and oteracil inhibits activation of 5-FU in the gut, resulting in lower toxic side effects there, such as diarrhoea.
Advertisement

TAS-114 and S-1 were given orally twice a day for 14 days before food, followed by seven days rest before repeating. The doses ranged from a starting dose of 5 mg/m2 (TAS-114) and 25 mg/m2 (S-1) up to 240 mg/m2 and 36 mg/m2 respectively. The trial aimed to determine the maximum tolerated dose and the recommended dose, while also looking at how well the drugs worked against the tumors and how they interacted with the body (pharmacokinetics and pharmacodynamics). In addition to the cancers already mentioned, patients with cancers of the liver, biliary tract, endometrium and stomach were included.

The most recent data from the trial presented at the Symposium showed that 15 of the patients were able to continue receiving the treatment for more than six months without their disease progressing. In addition, tumor responses were observed in three of the patients with non-small cell lung cancer, one with pancreatic cancer, one with breast cancer and one with colorectal cancer.

Dr Aoyama said: "These results show favourable responses across all the tumor types and they were particularly outstanding in patients with non-small cell lung cancer where we saw robust partial tumor responses and good disease control rates. We consider that to be able to control disease for a period as long as six months and beyond provides a significant clinical benefit to patients who had all been previously heavily treated.

"In addition, we saw no additional toxic side effects in patients who were given the drug combination above what is expected with S-1 alone. Patients tolerated the treatment well and the side effects were manageable. These findings warrant further investigation of the drug combination in a phase II clinical trial."



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Test  Your Knowledge on Heart
Test Your Knowlege on Genes
Obesity in Teens Make Inroads into Early Atrial Fibrillation
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Cancer and Homeopathy Signature Drug Toxicity Cancer Facts Cancer Tattoos A Body Art Drugs Banned in India Common Lifestyle Habits that Cause Diseases Health Benefits of Dandelion Plant Immune Checkpoint Inhibitors for Cancer Treatment 

Most Popular on Medindia

Find a Hospital Drug - Food Interactions Hearing Loss Calculator Loram (2 mg) (Lorazepam) Blood - Sugar Chart Color Blindness Calculator Diaphragmatic Hernia Noscaphene (Noscapine) Sinopril (2mg) (Lacidipine) Drug Interaction Checker
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

New Experimental Drug Shows Promising Result in Advanced Stage Cancer Treatment Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests